The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment
Age ≥18 years old, both male and female;
patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;
Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;
The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;
Pregnant or lactating women;
Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);
Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);
Patients who, in the judgment of the investigator, are not suitable for inclusion.
Patients with advanced gastric cancer confirmed by pathology or histology
Cohort
Prospective
Camrelizumab
Drug200mg,iv,d1,Q2W/Q3W
apatinib
Drug250mg,qd
chemotherapy
DrugStandard treatment
Objective response rate
The percentage of subjects achieving complete or partial response in a real-world clinical setting.
Progression free survival
From date of admission until the date of first documented progression in the real-world setting or date of death from any cause, whichever came first, assessed up to 24 months.
Disease control rate
The percentage of subjects achieving complete response, partial response, or disease stability in a real-world clinical setting.
Overall survival
From date of admission until the date of death from any cause, assessed up to 24 months.
Click on the lead sponsor to view all of their trials.
